Bio Green Med Solution, Inc. (BGMS)
1.39
+0.04
(+2.96%)
USD |
NASDAQ |
Dec 19, 16:00
1.375
-0.02
(-1.08%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.202M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -97.39% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 70.75 |
| Price to Book Value | 0.3103 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 36.00 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0007 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ. |
| URL | http://www.cyclacel.com |
| Investor Relations URL | http://investor.cyclacel.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 15, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 29, 2025 |
Ratings
Profile
| Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ. |
| URL | http://www.cyclacel.com |
| Investor Relations URL | http://investor.cyclacel.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 15, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 29, 2025 |